Creative Medical Technology Holdings shares are trading higher after the company announced FDA authorization for an expanded access therapy using CELZ-20.
Portfolio Pulse from Benzinga Newsdesk
Creative Medical Technology Holdings' shares surged following the FDA's authorization for expanded access therapy using CELZ-20, indicating a positive development for the company and its stakeholders.
March 07, 2024 | 3:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Creative Medical Technology Holdings' stock price is likely to experience a short-term increase following the FDA's authorization for expanded access therapy using CELZ-20.
The FDA's authorization for expanded access therapy is a significant milestone for Creative Medical Technology Holdings, indicating potential for increased investor confidence and positive market reception. This regulatory approval suggests a promising outlook for CELZ-20's development and deployment, likely leading to increased investor interest and a short-term uptick in CELZ's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100